Poly (<scp>ADP</scp>) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer
Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Shi‐Yong Sun(Emory University), Jeanne Kowalski(The University of Texas at Austin), Gabriel Sica(Emory University), Gregory Doho(Emory University), Jan H. Beumer(Johns Hopkins University), Susan M. Christner(Utrecht University), Zhengjia Chen(Hunan University of Traditional Chinese Medicine), Jeffrey M. Switchenko(Emory University), Alice P. Chen(National Institutes of Health), Michael R. Rossi(Sema4 (United States)), Fadlo R. Khuri(American University of Beirut Medical Center), Suresh S. Ramalingam(Emory University), Chunyang Li(Qingdao University), Sungjin Kim(Cedars-Sinai Medical Center), Xingming Deng(Emory University), Sandy Strychor(University of Pittsburgh), Ping Yue(Emory University), Guojing Zhang(Emory University)
Cited by 90
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
|Proceedings of the National Academy of Sciences|2017|899